US2016220633A1PendingUtilityA1

Macrocyclic inhibitors of flaviviridae viruses

46
Assignee: SELCIA LTDPriority: Jun 8, 2012Filed: Apr 8, 2016Published: Aug 4, 2016
Est. expiryJun 8, 2032(~5.9 yrs left)· nominal 20-yr term from priority
Inventors:Caroline AciroJean-Yves Christophe ChivaDavid Kenneth DeanAdrian John HightonPetr JansaAndrew John KeatsLinos LazaridesRichard L. MackmanKarine G. PoullennecAdam J. SchrierDustin SiegelVictoria Alexandra SteadmanGreg Watt
A61P 43/00A61P 37/02A61P 35/00A61P 3/04A61P 31/14A61P 31/12A61P 29/00A61P 31/18A61P 31/00A61P 31/20A61P 1/14A61P 1/16A61P 11/00A61K 45/06A61K 39/29A61K 39/05C07D 498/08A61K 38/15C07D 498/22C07D 498/18C07D 487/08C07K 5/0202A61K 38/12C07K 5/02C07D 513/18A61K 38/00A61K 31/504Y02A50/30
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 37 . (canceled) 
     
     
         38 . A method of treating a Flaviviridae viral infection in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester or prodrug thereof. 
     
     
         39 . A method according to  claim 38  wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester or prodrug thereof. 
     
     
         40 . A method according to  claim 38  wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         41 . A method according to  claim 38  wherein the Flaviviridae infection is caused by a virus selected from the group consisting of West Nile virus (WNV) Japanese encephalitis virus (JEV), tick-borne encephalitis virus, Junjin virus, Murray Valley encephalitis, St Louis enchaplitis, Omsk hemorrhagic fever virus and Zika virus. 
     
     
         42 . A method according to  claim 38  wherein the Flaviviridae infection is caused by Zika virus.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.